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Abstract
The ubiquitin proteasome system is involved in a myriad of biological functions including
cell cycle progression, intracellular signaling and protein degradation. As such, it is not
surprising to find many components of the system misregulated in cancer. The clinical
success of Bortezomib for treatment of multiple myeloma proves that targeting the
ubiquitin proteasome system is valid and feasible. Here, a detailed examination of the
strategies used to target the ubiquitin proteasome system in cancer is discussed. The inhib-
itors available, its targets, the cancer type and the developmental stage it is in are discussed.
Keywords: ubiquitin, proteasome, E1, E2, E3, ubiquitin proteasome system, cancer,
deubiquitinase, DUBs inhibitors
1. Introduction
The function and activity of most proteins can be partially modulated by posttranslational
modifications (PTMs). In particular, ubiquitination has emerged as one of the most versatile
PTMs over the past few decades. Ubiquitination is a process that attaches ubiquitin, a short
polypeptide of 76 amino acids, for its covalent link to proteins. It is a highly conserved process
that mostly targets unwanted proteins for degradation either through proteasome-mediated or
by directly sorting proteins to the lysosome and thus helps to maintain cellular homeostasis [1].
However, ubiquitination may also play a crucial role in other non-proteolytic regulatory
functions such as protein activation, interaction, and translocation [2].
Ubiquitination is a multistep process and requires the sequential action of three enzymes, the
E1 activating enzyme, E2 conjugating enzyme, and E3 ligase [3, 4] (Figure 1). The process of
ubiquitin attachment commences when E1 recruits free ubiquitin in the cell through its active
cysteine residue. The C-terminal glycine residue of ubiquitin is activated through ATP-dependent
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adenylation and thioester bond formation catalysed by E1, resulting in attachment by non-
covalent linkage to the E1 cysteine residue [5–7]. Activated ubiquitin is then transferred from
E1 to a cysteine residue of the E2 conjugating enzyme linked through a thioester bond [4, 8].
The E3 ligases are responsible for substrate recognition and facilitates transfer of ubiquitin to
the substrates from E2 resulting in covalent attachment of ubiquitin to the substrate’s lysine
residue [4, 9, 10]. The two major classes of E3s are the RING and HECT domain E3s which
transfer ubiquitin through different mechanisms [9, 10]. HECTdomain ligases accept ubiquitin
from E2 through its catalytic cysteine residue and act as an intermediate entity capable of
transferring ubiquitin to its recruited substrate [10]. RING domain ligases, instead of directly
transferring ubiquitin, function as scaffolds and allow ubiquitin transfer from the E2 directly to
the substrate [9]. In addition, other E3 classes such as ring-between-ring E3s are not discussed
here [11].
Moreover, the ubiquitin molecule itself contains seven intrinsic lysine residues (K6, K11, K27,
K29, K33, K48, and K63) and Met1 that can be further ubiquitinated allowing for the formation
of various types of ubiquitin chains [12]. These come in the form of linear, branched, forked,
homotypic, heterotypic kinds of monoubiquitin, multi-monoubiquitin, and polyubiquitin
chain types. Each type could be associated with distinct cellular functions. For example, one
of the best-known polyubiquitinations is K48-linked ubiquitination which acts as a degrada-
tion signal targeting substrate for proteasomal degradation [13].
The degradation of polyubiquitinated proteins is subsequently carried out in the 26S macro-
molecular proteasome complex which is present in both the cytosol and nucleus of eukaryotic
Figure 1. Schematic representation of ubiquitin conjugation cascade and inhibitors targeting specific cascade component.
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cells [14]. These complexes keep the proteins under quality checks and help cells to degrade
misfolded/unwanted proteins. The proteasome is an approximately 2.5 MDa proteinase com-
plex containing the catalytic active 20S core particle and the regulatory 19S particles [15, 16].
The 20S core particle is a barrel-shaped structure containing four stacked rings with two outer
α-rings and two inner β-rings [17]. Each ring is composed of seven distinct α (α1–α7) or
β (β1–β7) subunits [17]. The outer α-ring serves as the “gate” for entry of substrates, while the
β-rings contain the catalytic activity. Namely, β1, β2, and β5 subunits confer the peptidyl-
glutamyl-hydrolysing or caspase-like, the trypsin-like, and the chymotrypsin-like activity,
respectively [17].
The 19S subunit can be separated into the “base” and “lid.” The base contains ATPase subunits
(RPT1–6) and four non-ATPase subunits (Rpn1, 2, 10, 13) [17]. The non-ATPase subunits are
ubiquitin receptors that identify ubiquitinated substrates [17]. The lid contains nine subunits
(Rpn3, 5–9, 11, 12, 15) and two proteasome-associated deubiquitinating enzymes (UCHL5/
Uch37, Ubp6/Usp14) [17, 18]. Together with Rpn11/PSMD14, UCHL5/Uch37 and Ubp6/Usp14
carry out the deubiquitination of substrates before it moves on to the 20S core for degradation
[17]. Although it is generally assumed that ubiquitinated proteins end up degraded by the
proteasome, a recent review highlighted the strict requirements needed for proteasomal deg-
radation wherein certain ubiquitinated substrates which do not meet these requirements
escape from the proteasome and survive degradation [18].
Figure 2. Pictorial representation for involvement of DUBs in different functions.
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The ubiquitination process is antagonized by another set of enzymes that specifically removes
ubiquitin moieties and counteracts ubiquitin-mediated function of a protein. These specific
enzymes are called deubiquitinating enzymes (DUBs). As the name suggests, DUBs are respon-
sible for cleaving the isopeptide bond between protein and ubiquitin. Other than regulating
stability and function of its substrates, DUBs are also involved in ubiquitin precursor processing,
ubiquitin recycling, and ubiquitin chain editing (Figure 2). By conducting the process of remov-
ing ubiquitin from its target, DUBs are mostly involved in opposing the effect of ubiquitination
on substrates and thus leave a remarkable impact in the field of protein biology.
2. History of the ubiquitin proteasome system
The 2004 Nobel prize for Chemistry was awarded to Avram Hershko, Aaron Ciechanover, and
Irwin Rose for the discovery of ubiquitin-mediated protein degradation [19]. Remarkably, the
ubiquitin proteasome system (UPS) has been implicated in multiple cellular processes such as
cell cycle, stress response, and DNA damage repair [20]. In 1978, Hershko and Ciechanover for
the first time showed that ATP-dependent degradation required more than one component
[21]. Using reticulocyte lysate and a DEAD cellulose column, they separated 2 fractions that
individually do not catalyze ATP-dependent degradation but when combined, restored prote-
olysis [21]. Shortly after, the 2 fractions were identified. Fraction 1 contained ATP-dependent
proteolysis factor 1 (APF-1) which was later identified to be ubiquitin [21–23]. Together with
Irwin Rose, Aaron Ciechanover and Avram Hershko identified fraction 2 by further separating
it into 2 other fractions containing a 450 kDa protein unknown at that time the proteasome,
and the protease system containing E1, E2 and E3 enzymes [24]. It should be noted that prior
to this, ubiquitin was first identified by Goldstein in 1975, as a universally present polypeptide,
although its function was unknown at that time [25]. Prior to these findings, two reports in
1977 had characterized histone H2A covalently tagged with a single ubiquitin. Although not
for degradation, the finding implied that ubiquitin could be used for tagging [26, 27]. Subse-
quently, a series of papers from the Nobel laureates characterized and defined the multi-step
ubiquitin-tagging model for protein degradation through the E1, E2, and E3 enzymatic cascade
[4–7, 28, 29]. Additionally, multiple ubiquitin could be tagged to a single molecule of lysozyme
showcasing the first polyubiquitin chain [28].
Up till this point, the remaining piece of the puzzle was to identify the downstream protease(s)
responsible for degradation of the tagged proteins. In order to characterize the protease(s)
responsible, two large multi-subunit proteinase complexes were purified from reticulocytes
[15, 16, 30]. One of which requires ATP to degrade the tagged protein (~1500 kDa), while the
other is ATP independent (~700 kDa). It was later discovered that these were the 26S
proteasome and the 20S core catalytic subunit of the proteasome, respectively [15, 31, 32].
Apart from the ATP-dependent E1 ubiquitin activation step, the process of degradation by
the protease was also ATP dependent although the mechanism was unknown [33, 34]. This
was resolved when it was found that the assembly of the 26S proteasome from the 20S catalytic
core and 19S regulatory subcomplex is ATP dependent, explaining the reliance of energy for
substrate degradation by the proteasome [31, 35].
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The first papers to show a biological role for the ubiquitin cascade were in 1984 [36, 37]. In a
mutant mouse cell line (ts85) that is conditionally lethal and temperature sensitive,
monoubiqutinated H2A disappears at high temperatures, suggesting defects in the ubiquitin
cascade [38, 39]. As it turns out, the E1 enzyme in ts85 was temperature sensitive, resulting in
defects in ubiquitination at high temperatures [36, 37]. Additionally, the cells were arrested at
G2 at higher temperature, indicating a role of the UPS in cell cycle regulation. These two
papers set the stage for further discovery of biological roles played by the ubiquitin cascade
in the coming years [20].
The first observation of deubiquitinating activity was in fact, in the very paper that the first
scheme of ATP-dependent degradation was proposed [28]. Specifically, removing ATP from
the 125I-labeled ubiquitin-tagged lysozyme in the presence of endogenous proteins reversed
the ubiquitin tagging, implying the presence of a DUB which the authors described as an
amidase [28]. Subsequently, the first deubiquitination assay was developed and showed the
deubiquitinating activity of mammalian ubiquitin C-terminal hydrolase L3 (UCHL3) and its
yeast homolog Yuh1, which represented the first DUBs identified and characterized [40, 41].
The work of Varshavsky and colleagues ensued, identifying DUBs in yeast and up till today,
there are a total of ~80 known DUBs [42, 43].
3. Ligases in cancer
Since ubiquitination occurs through a multi-step cascade, it can be inferred that multiple proteins
along the cascade can be targeted. In particular, inhibitors targeting all three (E1, E2, and E3)
classes of enzymes are utilized both in research and clinics. For an overview, the inhibitors that
are about to be discussed in this section and the class of enzyme (E1, E2, and E3) which is
targeted are summarized in Figure 1.
3.1. E1 enzymes
UBE1 and UBA6 are the only two E1 enzymes that are known in humans [44]. Till date, there
are only two UBE1 inhibitors, PYR-41 and PYZD-4409 [45, 46]. Among the two, PYR-41 has
been shown to inhibit the nuclear factor ĸB(NF-ĸB) pathway by regulating the stability of
inhibitor of NF-ĸB (IĸB). Additionally, it also prevents the degradation of the tumor suppressor
p53 resulting in increased transcriptional activity of p53 [45]. On the other hand, PYZD-4409
was specifically shown to induce ER stress-induced apoptosis in cancer cells and, in a mouse
model of leukemia, delayed tumor cell growth [46]. Although these results suggest the potential
of targeting E1 in cancer treatment, none of these are currently in clinical trials, perhaps due to
off-target effects or poor pharmacokinetic properties.
3.2. E2 enzymes
There are ~38 E2 enzymes in the human genome implying that they serve as more specific
targets than E1 [8]. CC0651 is an allosteric inhibitor of CDC34, the common E2 enzyme for
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Cullin ligase complexes. Treating cancer cells with CC0651 results in the accumulation of the
tumor suppressor p27 and inhibition of proliferation, which suggests that CC0651 could be a
potential inhibitor for clinical use [47]. However, development of this compound has met with
great difficulties due to pharmacokinetic reasons [48]. Another potential target in cancer is the
E2 enzyme UBC13-UEV1A, an important regulator of NF-ĸB pathway induction through the
formation of ubiquitin K63-linked chains. The inhibitor NSC697923 has been shown to inhibit
the formation of K63-linked chains by UBC13 in vitro and is effective in inhibiting the prolifer-
ation and survival of diffuse large B-cell lymphoma (DLBCL) [49]. BAY-11-7082 is a well-
known inhibitor of the NF-ĸB pathway and has been thought to inhibit the IĸB kinases [50].
However, it was found to inhibit the E2 UBC13 by preventing ubiquitin conjugation to it,
thereby preventing K63-linked chain formation in the same way as NSC697923 [50]. Likewise,
it was shown that BAY-11-7082 induces cell death to DLBCL HBL-1 cells [50]. Although E2
inhibitors show immense potential for cancer treatment, so far, E2 inhibitors are present only
in preclinical stages.
3.3. E3 enzymes
Amongst enzymes in the ubiquitin conjugation cascade, E3s are the most abundant in number
with ~700 ligases identified so far [48]. Due to the large number, targeting E3 will likely
increase the specificity and decrease side effects. Due to space limitation, we will be discussing
a few of the E3 ligases that are implicated in cancer and refer the readers to the following
review about E3 ligases family [51].
3.3.1. Mouse double minute 2 homolog (MDM2)
Termed the guardian of the genome, p53 is frequently upregulated in stress conditions and
functions to activate the expression of genes involved in apoptosis and cell cycle arrest to
prevent cellular transformation [52]. MDM2 is an E3 ligase of p53 responsible for its degrada-
tion and is frequently upregulated in cancer [53, 54]. Thus, targeting MDM2 could be useful for
cancer treatment. To this end, several MDM2 inhibitors are available. In particular, the Nutlin
family of cis-imidazoline inhibitors shows the greatest potential [55]. One of the latest devel-
oped Nutlin inhibitors, RG7112, has been tested in phase I clinical trials and shows activity
against relapsed leukemia [56]. Although it showed good clinical outcomes, a high dose was
required and it caused gastrointestinal side effects [56, 57]. A more potent pyrrolidine-based
MDM2 inhibitor, RG7388 is currently in clinical trial and might be able to overcome these
issues [58]. In preclinical setting, RG7388 showed potent tumor inhibition specifically in p53
wild-type xenograft neuroblastoma indicating its possible use in neuroblastoma treatment
where majority of tumors are p53 wild-type at diagnosis [59].
A majority of MDM2 inhibitors bind to MDM2 itself to prevent it from binding to p53. RITA
(reactivation of p53 and induction of tumor cell apoptosis), however, binds to p53 and pre-
vents MDM2 from interacting [60]. In this case, the mechanism of stabilization might be
MDM2 independent and could possibly be used to treat MDM2-independent p53-destabilized
cancers. Thus far, the mentioned MDM2 inhibitors aim to restore p53 levels. Given that p53 is
known to be mutated in ~50% of all cancers, these therapies are severely limited to a subpop-
ulation of p53 wild-type tumors [48, 61]. An ingenious way to overcome this is through the use
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of drugs, which restore mutant p53 function. One example of such an approach is the drug
PRIMA-1 which alkylates the thiol groups of mutant p53, correcting protein folding and
enabling p53 to carry out its tumor suppressive function [62].
3.3.2. S-phase kinase associated protein 2 (SKP2)
SKP2 is a F-box protein which functions as the substrate recognition subunit of the SCF
(SKP1/Cullin/F-box) RING E3 ligase complex [63]. In particular, its role in ubiquitinating and
degrading cell cycle regulators, p27 and p21 makes it a potential target in cancer [64, 65].
Additionally, SKP2 is upregulated in several different cancers and serves as a prognostic
marker for cancer patient survival [66–68]. Particularly, a structural pocket formed by SKP2
and its neighboring subunit CKS1 within the SCF complex is important for binding and
degradation of p27. This outlines a potential vulnerability which could be targeted in cancer
therapy. As such, using in silico screening to identify inhibitors for this structural pocket, four
compounds were shown to increase p27 levels and arrest cells at G1 [69]. Another mechanism
that could be utilized to inhibit SKP2 could be by targeting its association with the SCF complex
through inhibiting SKP1-SKP2 binding. SZL-P1-41was identified to block SKP1-SKP2 interaction
and shows strong antitumor effects against lung and prostate tumor xenograft in mouse models
with concomitant increase of p27 [70]. Lastly, CPDA is another compound identified due to its
ability to inhibit in vitro ubiquitination of p27 by SCF complex [71]. Although its mechanism is
unknown, it has been shown to induce cell cycle arrest specifically in leukemic cells but not
marrow components [71].
3.3.3. Beta-transducin repeat containing E3 ubiquitin protein ligase (βTrCP)
Like SKP2, βTrCP is a component of the SCF-Cullin E3 ligase complex. It utilizes its N-terminal
F-box domain to bind to SKP1 and its C-terminal WD40 domain to bind to substrates includ-
ing pro-caspase-3, IĸB, p53, CDC25, and WEE1. In most cancers, it is upregulated and acts as
an oncogene [72]. Erioflorin and GS143 are two βTrCP inhibitors that block the interaction of
βTrCP with its targets, PDCD4 and IĸB, respectively, leading to their stabilizations [73].
3.3.4. RING box protein 1/RING box protein 2 (RBX1/RBX2)
Both RBX1 and RBX2 are important subunits of the SCF complex and function to physically
bring the activated E2 closer to the substrate for ubiquitination [74]. Increased expression of
RBX1 is seen in breast, liver, kidney, and lung cancer indicating an oncogenic function [75]. An
exception is in melanoma where RBX1 is higher in nevi than in melanomas [76]. Likewise,
RBX2 is overexpressed in many human cancers and targets IĸB, c-Jun, HIF-1α, and NF1 for
degradation [75]. Although its precise mechanism in cancer progression is not well studied,
depletion of RBX2 induces apoptosis, decreases tumor growth, and sensitizes cells to DNA
damage [77, 78].
3.3.5. Inhibitor-of-apoptosis proteins (IAPs)
The IAPs are RING E3 ligases that inhibit caspases and thereby block apoptosis which makes
them putative targets in cancer [79]. During apoptosis, the second mitochondria-derived
activator of caspase (SMAC) is released from the mitochondria and binds IAPs which releases
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caspases to perform their pro-apoptotic function. IAPs such as c-IAP1 and c-IAP2 are reported
to have genomic amplifications in a variety of cancers like hepatocellular carcinoma, cervical,
pancreatic and esophageal cancers. SMAC on the other hand gave a better prognosis in breast,
colorectal, and bladder carcinomas [80]. Mimicking the SMAC binding region, a few inhibitors
were shown to bind IAPs and activate apoptosis in cancer. These are currently in phase I
clinical trials [80].
4. Ubiquitin proteasome system in virus-induced cancers
The idea of viral oncoproteins hijacking the cellular degradation system to degrade potential
tumor suppressors is exemplified by the early papers showing human papillomavirus (HPV)
oncoproteins E6 and E7 utilizing E6-associated protein (E6-AP) and Cullin 2 RING ligase to
target p53 and retinoblastoma for degradation, respectively [81–85]. By developing small
molecule inhibitors, targeting these ligases in virus-induced cancers holds great potential for
cancer therapy. Additionally, depleting E6-AP expression has been shown to increase p53
protein levels and inhibit growth in HPV-positive cells [86]. So far, inhibitors identified that
abalte E6-AP and E6 binding using binding assays have been disappointing as they show low
efficacy in inducing cell death in culture [86–88]. It is suggested that more structural data are
required in order to design better inhibitors [86]. On the other hand, the small molecule RITA
mentioned earlier was shown to block the binding of E6 to p53 thereby preventing E6-mediated
degradation degradation of p53 [89]. Cervical carcinoma xenografts showed substantial growth
suppression when treated with RITA, suggesting its potential use in cervical cancer [89].
Another important tumor suppressor targeted by the HPV E6 protein is Tat-interactive protein
60 kDa (TIP60) [90]. In addition to HPV E6, adenovirus oncoproteins were also reported to
target TIP60, implying an important tumor suppressive role played by TIP60 in virus-induced
cancer [91]. The mechanism of degradation in HPV-positive cells involves the use of E3
identified by Differential Display (EDD1) to ubiquitinate and target TIP60 to the proteasome
[92]. Importantly, overexpression of TIP60 or depletion of EDD1 in cervical cancer mouse
xenografts inhibited tumor growth implying that EDD1 could be a novel target in cervical
cancer therapy [92]. In addition, EDD1 is also upregulated in ovarian, breast, and pancreatic
adenocarcinoma, as such an EDD1 inhibitor could be extended to these cancers [93].
Latent membrane protein 2A (LMP2A) is one of the 9 proteins expressed from Epstein-Barr
virus transformed genome and is involved in viral latency and persistence [94]. In order to
perform its function, it recruits neural precursor cell-expressed developmentally down-regulated
4-like (NEDD4-like) ligase to facilitate degradation of Lyn, a tyrosine kinase [94, 95]. This in turn
blocks signal transduction of B-cell receptor. Although the mechanism is not completely under-
stood, it increases our understanding of how cellular ligases are utilized at different stages of
viral-induced cancers [95].
Apart from individual ligases utilized by viral proteins to degrade cellular substrates, there
have been many cases reported where viral oncoproteins interact with the proteasome and
hijacks it for their own purposes [95]. For example, through binding to the 20S proteasome and
the NF-ĸB precursor p105, Tax, which is the human T-cell leukemia virus (HTLV) oncoprotein,
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enhances the proteolytic activation of NF-ĸB, which sustains T-cell proliferation [95–97]. In
particular, this represents a potential susceptibility using proteasome inhibitors in HTLV-
infected T-cell leukemia treatment. Indeed, treatment with proteasome inhibitor Bortezomib
was investigated in mouse models with mixed results [98, 99]. In HTLV-1-associated xenograft
models, Bortezomib inhibited tumor growth and the mice showed prolonged survival [98, 99].
However, heterogeneity in responsewas seen between tumors treated with vehicle or Bortezomib
derived from Tax transgenic mice [98]. More studies need to be conducted before proteasome
inhibitors could be used for HTLV infected T-cell leukemia.
Hepatitis B virus X-antigen (HBX) is another oncoprotein known to interact with proteasome
subunits PSMA7 and PSMC1 [100]. In the presence of HBX, two well-defined proteasomal
substrates had increased half-lives suggesting that HBX can block proteasomal activity [100].
The importance of proteasome inhibition by HBX is shown in its ability to regulate HBV virus
replication. Particularly in cells infected with mutated HBV not expressing HBX, proteasomal
inhibitors MG132 and Epoxomicin were able to rescue virus replication back to wild-type
levels supporting HBX’s role in inhibiting proteasome [101, 102].
Apart from the proteasome, HBX also binds to cellular DDB1, a subunit of the Cullin 4 RING
ligase (CRL4) complex [101]. Rather than being degraded by the CRL4 complex, it is stabilized
and has been suggested to alter CRL4 specificity by displacing DDB1-CUL4-associated factors
(DCAFs), which are proteins that confer substrate specificity to the CRL4 complex [103, 104].
Indeed, two recent papers identified structural maintenance of chromosomes 5/6 (SMC5/6) as
novel degradation targets of the CRL4-HBX complex [105, 106]. Since SMC5/6 complex is
essential for inhibiting the extrachromosomal HBV gene expression, identification of SMC5/6 as
CRL4-HBX targets solves the long-standing question of howHBX-DDB1 interaction is important
in HBV virus replication [101, 107, 108]. From these data, one plausible strategy would be to
design inhibitors to block the interaction between HBX and DDB1 or the proteasome.
5. Families of deubiquitinating enzymes
There are approximately 80 functional DUBs known in humans [109]. These DUBs are mainly
divided into six different classes based on their structure and active site homology: ubiquitin
specific proteases (USPs), ubiquitin carboxyl-terminal hydrolases (UCHs), ovarian tumor pro-
teases (OTUs), Machado-Joseph disease protein domain proteases (MJDs), JAMM/MPN (JAB1/
MPN/MOV34 metalloenzyme) domain associated metallopeptidases (JAMMs), and monocyte
chemotactic protein-induced protein (MCPIP) [110] (Figure 3). All DUB families belong to
cysteine proteases with the exception of JAMMs family of DUBs, which are zinc-dependent
metalloproteases. The mechanism of action for cysteine-dependent DUBs is through nucleo-
philic attack on the isopeptide linkage of an ubiquitinated lysine residue by the catalytic
cysteine, which is facilitated by a nearby histidine side chain that helps to decrease the pKa of
the cysteine. A third residue, aspartic acid or asparagine, helps in this whole process. This
residue aligns and polarizes the catalytic histidine. Some enzymes which do not have this third
residue use other means to polarize histidine [111, 112]. On the other hand, the mechanism of
action for JAMMs which are metalloproteases is facilitated by two zinc ions which are present
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within its catalytic site and coordinated by invariant histidine, aspartic acid, and serine side
chains [113]. This zinc ion activates a water molecule to form a hydroxide ion which in turn
attacks the carboxyl carbon in the isopeptide link [114].
Out of the six classes of DUB families, the USP family is the largest with more than 50
members. These proteins belong to cysteine protease family (clan CA, family C19) [115]. USPs
are characterized by the presence of a catalytic core involving histidine and cysteine boxes
[116]. DUBs from the USP family contain a highly conserved USP domain characterized by
three subdomains which form the palm, thumb, and fingers of a right hand [117]. The active
site cysteine is present between the palm and thumb while the finger is used for interaction
with ubiquitin. CYLD (cylindromatosis D) is the only USP which does not have the finger
domain but possesses an additional domain known as B-box domain [118]. The presence of
additional domain and terminal extensions has also been seen in several other USPs, which
plays critical roles in conferring specificity to DUBs. For example, USP3, USP5, USP39, USP44,
USP45, USP49, and USP51 have zinc finger USP domain, USP25 and USP37 contains ubiquitin-
interacting motif, USP5 and USP13 possess ubiquitin-associated domain, USP4, USP11, USP15,
USP20, USP33, and USP48 have the domain in USPs (DUSP), and USP52 has the exonuclease III
domain. Moreover, several USPs such as USP4, USP7, USP14, USP32, USP47, andUSP48 have the
ubiquitin-like domain which can be found within and outside of the catalytic domain [115, 119].
UCHs are another family of DUBs, which contain four members in humans, UCHL-1, UCHL-
3, UCHL-5, and BAP1. This class of DUBs was the first to be structurally characterized. In
particular, UCHs have a short catalytic domain of approximately 200–300 amino acids [109]
and can only target short peptide from the C-terminus of ubiquitin because of the presence of a
confined loop which prevents polyubiquitin chain recognition and large protein processing. A
well-studied member of the UCH class of DUBs is UCHL-1, which is one of the shortest DUBs,
having only 223 amino acids [120]. UCHL-1 was initially known to be involved in ubiquitin
Figure 3. Schematic representation of different families of deubiquitinating enzymes and their members.
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maturation by cleaving single amino acids or short peptides from the C-terminus of ubiquitin
precursors to generate mono-ubiquitin rather than cleaving ubiquitin from proteins [121].
In UCHL-5 and BAP1, there is the presence of additional C-terminal extension of about 100 and
500 amino acids, respectively. The additional extension at the C-terminus of UCHL-5 directs it to
proteasome and helps in trimming polyubiquitin chain from conjugated protein as they are
degraded [122]. However, the additional extension of BAP1 contains a nuclear localization signal
and helps it to interact with the N-terminal ring finger of BRCA1 (a ubiquitin ligase) [122, 123].
Due to space limitation, we have summarized the targets of different USPs and UCHs in
cancer in Table 1.
DUBs
family
DUBs Important targets (direct/
indirect)
Mechanism/pathway Relevance to neoplasm
Ubiquitin
specific
proteases
(USPs)
Cylindromatosis
(CYLD)
TNFR-associated factor 2
(TRAF2) and TRAF6 [197]
Promotes apoptosis [198];
negatively regulates NFĸB
signaling [197]
Downregulated in lung cancer
[199], liver cancer [200], colon
cancer [200] and multiple
myeloma [201]
USP1 Fanconi anaemia
complementation group D2
(FANCD2) [202];
proliferating cell nuclear
antigen (PCNA) [203]
Involved in DNA repair and
DNA-damage response
pathways [202]
Overexpressed in hydatidiform
mole [204]
USP2 MDM2 [205], MDMX [206],
Cyclin D1 [207]
Indirect regulation of tumor
suppressor p53; increase cell
proliferation [208]
Associated with bladder cancer
and increase in proliferation,
invasion and migration in
bladder epithelial cells [209];
overexpressed in prostate cancer
[210]
USP4 TGFβRI [211] Regulates TGFβ signaling
pathway [211]; important player
mediating crosstalk between
TGFβ and PI3K signaling
pathway [211]
Upregulated in human
hepatocellular-carcinoma
samples and has been suggested
to induce aggressive phenotype
[212]; downregulated in small
cell lung cancer cell lines [213]
USP5 p53 [214] Inhibits accumulation of free
unanchored polyubiquitin
chains
USP7 p53 [187], PTEN [188],
IRS1/2 [215], Chk1 [216],
Claspin [217]
Regulates stability of p53 and
MDM2 [218]; reported to induce
IGF signaling [215]; modulates
ATR-Chk1 pathway [216, 217]
Overexpressed in prostate
cancer [188]
USP8 EGFR [219]; ERBB2, ERBB3
and MET [220]
Regulates endosomal ubiquitin
dynamics and required for RTK
downregulation following
internalization [221, 222]
Gain-of-function mutation in
Cushing disease [223]; depletion
of USP8 leads to selective death
of Gefitinib resistant non-small
cell lung carcinoma (NSCLs)
cells [220, 224]
USP9X SMAD4 [225], β-catenin
[226]
Regulates signaling pathway
such as TGFβ [225] and MAPK
pathway [227]
Overexpressed in breast cancer
[228], ERG-positive prostate
tumors [229] and osteosarcoma
cell line SaOS2 [230] and its
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DUBs
family
DUBs Important targets (direct/
indirect)
Mechanism/pathway Relevance to neoplasm
increased expression has been
correlated with ill prognosis
outcomes in multiple myeloma
patients [231] and esophageal
squamous cell carcinoma [232]
USP10 p53 [233], T-box
transcriptional factor (T-
bet) [234]
Regulates ATM-p53 and
mismatch repair (MMR) [235,
236]
Overexpressed in breast cancer
[228], glioblastoma [237] and in
metastatic melanoma [147]
USP11 TGFβRII [238], p53 [239] Regulates TGFβ signaling
pathway [240] and BRCA2
mediated damage response
[241]
High expression of USP11 has
been observed in murine lung
tissue [238]
USP12 Androgen receptor (AR)
[242]
Suggested as a putative
regulator of progression and
metastasis in prostate cancer
[242]
USP13 PTEN [243] Implicated in PI3K signaling Important for melanoma growth
in soft agar assay and nude mice
[244]
USP15 TGFβRI [245], E6 (human
papilloma virus (HPV)
protein) [246]
Enhances TGFβ signaling
pathway [245]
Overexpressed in glioblastoma,
ovarian and breast cancer [245,
247]
USP16 Histone H2A Regulates progression of cell
cycle and gene expression [248]
Regulates stem cell self-renewal
and pathologies associated with
Down syndrome [249]
USP17 Ras-converting enzyme 1
(RCE1) [250]
Important for chemotaxis and
chemokinesis, and have a crucial
role in cell migration [251]
USP17 is amplified in tumors
and found to regulate G1/S cell
cycle advancement and
proliferation [252]
USP18 EGFR [253] Involved in interferon signaling
[254]
Implicated in regulation of viral
disease and malignancies;
identified as anticancer target in
acute promyelocytic leukemia
(APL) [254, 255]
USP19 KPC (Kip1 ubiquitination-
promoting complex) [256]
Regulates cell growth [256] Putative target for inhibiting
proliferation [256]
USP20 HIF1α [257], Claspin [258] Promotes transcription of
hypoxic response genes [257]
Decreased expression in gastric
cancer cells and negative
correlation with tumor size and
tumor invasion [258]
USP21 GATA3 [259], Histone H2A
[260], EZH2 [261]
Activates transcription [260] Upregulated in bladder
carcinoma [261], breast
carcinoma [262, 263] and cancer
stem-like cells (CSCs) of renal
cell carcinoma cell lines [263]
and its expression was
correlated with tumorigenic
behavior of cells such as tumor
size, proliferation, metastasis
and invasion
USP22 Histones H2A and H2B
[264]; c-MYC [265]
Regulates epigenetic
modulations that support
neoplastic change [264, 266];
involved in regulation of various
Elevated expression of USP22
has been reported to be
associated with ill prognosis of
several cancer like breast [268],
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DUBs
family
DUBs Important targets (direct/
indirect)
Mechanism/pathway Relevance to neoplasm
tumor associated processes such
as cell cycle, proliferation, and
apoptosis [267]
colorectal [269] and esophageal
squamous cell carcinoma [270]
USP25 Tankyrases (TNKS1 and
TNKS2) [271]
Regulates Wnt signaling
pathway [271]
The upregulated mRNA and
protein level of USP25 was
observed in NSCLC patients
which was linked to metastasis
[272]
USP28 c-MYC [273, 274], Chk2
[275], LSD1 (lysine-
specificdemethylase1) [276]
Involved in DNA damage
response [274, 275]
Somatic mutation has been
observed in case of lobular
breast cancer [277];
overexpressed in colon [278] and
breast cancer [273]
USP29 p53 [279], Claspin [280] Involved in regulation of p53
and ATR-Chk1 pathway
USP30
USP33 Interact with Robol [281];
CP110 (centriolar protein)
[169]
Required for Slit signaling [281];
involved in regulation of
centrosome duplication and
genomic stability [169]
Overexpressed in pediatric acute
lymphoblastic leukemia [282]
USP34 RNF168 [283], AXIN [284] Regulate genome stability [283];
positively regulates Wnt
signaling pathway [284]
USP42 p53 [285] Supports “protect and repair
function” of p53 without
altering its basal level [285]
USP44 Mad2-Cdc20 [286], H2B
[287]
Regulates mitotic spindle
checkpoint [286]
Overexpression in human
T-cell-leukemia [288]; defects
in chromatin segregation has
been observed with USP44
depletion [286]
USP47 Polβ [289] Regulates base excision repair
(BER) [289]
USP47 is suggested to be
possible therapeutic target as
USP47 depletion upregulated
level of Cdc25A and decreased
cell survival [290]
USP50 Cdc25B
Wee1 [291]
DNA damage response
signaling pathway [292]
Ubiquitin
C-terminal
hydrolases
(UCHs)
UCHL-1 p53 [293] Involved in ubiquitin
maturation [294] and activation
of AKT signaling pathway [295]
Linked to several types of cancer
including Breast [296], lung
[297], colorectal [298] and
pancreatic [299]
BRCA1-
associated
protein1 (BAP1)
Host cell factor 1 (HCF-1)
[300]
Participate in epigenetic
regulation in tumor and
regulation of histone stability
[301]
Mutated in melanoma [302] and
implicated in lung and breast
cancer [123]
UCHL-5 Smad2 and Smad3 [303];
NFRKB [304]
Promotes TGFβ signaling [303];
regulates DNA double-strand
breaks (DSBs) resection and
repair by homologous
recombination [304]
Overexpressed in epithelial
ovarian cancer [63] and
hepatocellular carcinoma [175]
Table 1. USP and UCH family of DUBs, their targets and relevance in cancer.
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Ovarian tumor (OTU) represents a superfamily of proteins which are characterized by the
presence of an ovarian tumor domain (OTUD) [124]. This domain was first described in the
ovarian tumor gene in fruit flies which is involved in the development of ovaries [125]. In 2003,
some members of the OTU superfamily were identified to have active cysteine protease site
and were described as deubiquitinating enzymes [126]. Based on its characteristics, this class is
further subdivided into four groups: Otubains, A20-like OTUs, OTUDs, and OTULIN like
OTUs [127]. According to recent studies, the OTU core domain is suggested to consist of five
β-strands placed between two αhelical domains. The helical domains vary in sizes among
OTU DUBs [128–130]. Like USPs, OTU members also possess additional domains. For exam-
ple, A20 has A20-type Zn fingers, TRABID has NP14-type Zn fingers, OTUD1 and OTUD5
have ubiquitin-interacting motif, and CEZANNE contains ubiquitin-associated domain [118].
In humans, there are 14 DUBs which belong to the OTU family of DUBs [124]. These DUBs are
able to cleave different linkages of ubiquitin chains. For example, OTUB1 and A20 specifically
remove K48-linked ubiquitin chains, CEZANNE is specific for K11-linked chains, and TRABID
cleaves K29- and K33-linked chains [131].
OTUB1 has a crucial role in DNA damage repair through regulating the RNF8/168 pathway.
Recently, OTUB1 is reported to be overexpressed in non-small-cell lung carcinoma (NSCLC)
and promotes RAS activation by inhibiting RAS monoubiquitination [132]. Moreover, high
expression of OTUD1 is also seen in thyroid carcinoma signifying its oncogenic nature [133].
On the other hand, OTUD5 is linked to apoptosis and is involved in stabilization and activa-
tion of p53, suggesting a possible tumor suppressive role [134].
A20 and CEZZANE take part in the negative regulation of NFκB signaling, whereas TRABID
positively regulates Wnt signaling pathway [135–137]. A20 is unique and known to have activity
of both an E3 ligase and a DUB [138]. A20 cleaves K63-linked ubiquitin chains from RIP1
(receptor interacting protein 1) and negatively regulates the NFκB pathway [137]. A20 genes
have been reported to be mutated/deleted in lymphoma suggesting it to be a tumor suppressor
[139]. On the other hand, increased A20 is associated with poor outcome in glioma patients [140]
and Tamoxifen resistance in breast cancer [141]. Overall, the widespread involvement of these
DUBs in a variety of tumorigenic processes makes them potential targets for cancer treatment.
The Josephin family of DUBs is named after a neurodegenerative disease known as Machado-
Joseph disease. Particularly, genetic mutations of ATXN3, a member of MJD class of DUBs, are
linked to the cause of Machado-Joseph disease [142]. There are four DUBs in humans that form
the MJD class: Josephin domain-containing protein 1 (JOSD1), JOSD2, ATXN3-like and ATXN3.
ATXN3 can cleave both K48- and K63-linked chains with a higher preference for K63 chains.
ATXN3 controls protein folding and stability by editing polyubiquitin chains [143]. The other
three members of the Josephin family (JOSD1, JOSD2, and ATXN3L) have highly conserved
catalytic triad formed by one cysteine and two histidine residues. An additional domain such as
ubiquitin-interacting motif has been identified in ATXN3 and ATXN3L, indicating probable
interaction between two distal ubiquitins in a polymer [144]. It has been reported that all
Josephin family DUBs especially ATXN3 inhibits PTEN transcription in lung cancer and inhibi-
tion of these DUBs induces PTEN expression [145]. In light of these observations, ATXN3 could
be a putative target for PTEN repressed tumors. JOSD1 is a membranous DUB and is involved in
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regulating membrane dynamics and endocytosis [146]. Moreover, JOSD1 was found to be
significantly overexpressed in NSCLCs but its function remains to be elucidated [147].
As mentioned earlier, the JAMM family of DUBs has zinc metalloprotease activity. The crystal
structure of AMSH-LP (associated molecule with SH3 domain-like proteases), a DUB from the
JAMM family, bound to K63-linked diubiquitin, assisted the understanding of catalytic mech-
anism of JAMM family [148]. The members of the AMSH family are involved in specific
removal of K63-linked polyubiquitin chains and regulate vesicle trafficking and receptor
recycling. The domain of AMSH-LP consists of a JAMM core and two conserved insertions.
JAMM proteases which do not have AMSH-specific inserts show no specificity for K63-linked
polyubiquitin.
There are 12 JAMM proteins along with AMSH-LP that are encoded by human genome. Seven
out of the 12 JAMM proteins have isopeptidase activity for ubiquitin or ubiquitin-like proteins
while the rest are catalytically inactive. The JAMM proteins with isopeptidase activities are:
AMSH-LP, AMSH/STAMBP, BRCC36 (BRCA1/BRCA2-containing complex subunit 36),
POH1/PSMD14 (26S proteasome-associated PAD1 homolog 1), MYSM1 (Myb-like with SWIRM
and MPN domains 1), MPND (MPN domain-containing protein), and CSN5/JAB1 (COP9
signalosome subunit 5). The high degree of similarity between POH1, AMSH, and AMSH-LP
sequences indicates a common mechanism for ubiquitin recognition and catalysis for these
JAMMs [148].
BRCC36 belongs to the JAMM class of DUBs whose overexpression has been observed in
breast cancer cell lines and tumors [149, 150]. EIF3H and COP6S are other examples of DUBs
that belong to JAMM class. COP6S is amplified in breast cancer [151] and EIF3H is amplified in
breast and prostate cancer [152].
MCPIP1 proteins possess a domain with deubiquitinating activity which suggests the presence
of a sixth family of DUBs in the human genome [153]. This family is suggested to have seven
members according to bioinformatics analysis of a recent study [110]. The interaction of
MCPIP1, which is the founding member of this family with ubiquitinated proteins, is carried
out by ubiquitin-associated domain placed at the N-terminus. However, this domain is not
essential for its DUB activity. The other domains of MCPIP1 proteins include N-terminal
conserved region, a conserved CCCH-type zinc-finger domain in the middle region of the
protein, and a proline-rich domain at its C terminus. The domains that are required for activity
of the MCPIP1 proteins are the N-terminal conserved region and zinc finger. In addition,
similar to cysteine proteases, the catalytic domain of MCPIP1 also consists of cysteine and
aspartic acid boxes but lacks histidine in the catalytic core. However, possibility of histidine
outside the core cannot be ruled out [153].
6. Targeting proteasome in cancer
The 26S proteasome is a 2.4 MDa multi-subunit complex responsible for the degradation of
intracellular proteins [154]. Currently, there are two FDA-approved proteasome inhibitors
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namely Bortezomib (Velcade) and the more potent Carfilzomib (Kyprolis) (Figure 1). The FDA
initially approved Bortezomib in 2003 for relapsed multiple myeloma (MM) patients [155].
Now, its use has been extended to new MM patients as well as for the treatment of mantle cell
lymphoma [156]. Generally, there are three well-accepted models. These are NF-ĸB inhibition
through stabilization of IĸB, activation of the unfolded protein response by proteasome inhibi-
tion due to high endoplasmic reticulum (ER) stress, and stabilization of pro-apoptotic proteins
such as BAX and NOXA [48, 155, 157, 158]. Carfilzomib was approved by FDA in 2012 for
relapsed and refractory MM patients, who had previously been treated with Bortezomib
[156, 157]. It binds irreversibly to proteasome and inhibits its function by up to 80% resulting
in nonfunctional proteasomes as such, it is used for Bortezomib-resistant MM patients [48].
6.1. Proteasome associated DUBs as therapeutic target
Although Bortezomib and Carfilzomib have shown great promise in the clinic [159, 160], it also
exhibits side effects [161]. As such, targeting proteasome-associated DUBs might present better
specificity by minimizing off-target toxicity attributed to inhibiting the entire proteasome
complex. These DUBs play two critical roles in the UPS system. First, by cleaving the attached
ubiquitin molecules, it promotes the entry of polyubiquitinated substrate to the 20S catalytic
portion of the proteasome. Second, the cleaved ubiquitin would then be available to be recycled
as free ubiquitin [162]. Considering the fact that DUBs are intrinsic part of ubiquitin-proteasome
system and majority of cancers demonstrate altered expression of DUBs which might drive a
number of cancer-associated pathways, targeting DUBs may be considered as a reasonable
approach for regulating UPS and is current area of research. There are three DUBs which are
associated with the proteasome: PSMD14 (or POH1), USP14, and UCHL5.
6.1.1. PSMD14
PSMD14 is a JAMM metalloprotease. Other than recycling ubiquitin, it is also essential for the
structure and function of the 26S proteasome [163]. The importance of PSMD14 in cancer is
seen in MM, where its level has been shown to be negatively correlated with the overall patient
survival [164]. Depletion of PSMD14 showed decrease in cell viability in multiple myeloma
cells. Moreover, upregulation of nuclear PSMD14 is reported in hepatocellular carcinoma and
correlates with E2F transcription factor 1 (E2F1) expression and cancer prognosis [165]. PSMD14
is also known to deubiquitinate and modulate the stability of ERBB2 [166]. In addition, PSMD14
has been reported to promote cellular responses to DNA double-strand breaks through homol-
ogous recombination. In light of these observations, targeting PSMD14 could lead to better
therapeutics in cancer patients.
6.1.2. USP14
Another DUB which is important for ubiquitin recycling is USP14 and has been shown to be
involved in delaying protein breakdown by the proteasome and thus, inhibits proteasome activity
[167]. USP14 perhaps does so by preventing deubiquitination of proteasome substrate by
PSMD14. Although USP14 depletion in mammalian cells has no detectable effect on the accumu-
lation of polyubiquitin [122], it has been shown to inhibit proteasome through its deubiquitinating
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activity. USP14 also assists substrate degradation by increasing 20S gate opening [168]. USP14 is
overexpressed in NSCLC [169] and in ovarian cancer cells [170]. The expression of USP14 in
NSCLC is associated with poor overall survival of patients and tumor cell proliferation, which
further strengthens the evidence of USP14 as a tumor-promoting factor in NSCLCs, and a
promising therapeutic target. Moreover, USP14 expression in colorectal cancer has been found to
be associated with liver and lymph node metastases [171]. It is also implicated in several impor-
tant signaling pathways [172, 173]. The small molecule inhibitor of USP14, IU1 was shown to
stimulate proteasome degradation, further proving its role in proteasome inhibition. This inhibi-
tor specifically binds and inhibits proteasome-bound USP14 [167].
6.1.3. UCHL5
Similar to USP14, UCHL5 is involved in removing ubiquitin from the distal tip of polyubiquitin
chains. However, in contrast to USP14, UCHL5 can only release mono-ubiquitin [174]. Clinically,
UCHL5 is overexpressed in epithelial ovarian cancer [63] and hepatocellular carcinoma [175]. It
has been shown to be associated with poor clinical outcomes in epithelial ovarian cancer [63] and
promotes cell migration and invasion in hepatocellular carcinoma [175], implying that it could be
a novel predictor of hepatocellular carcinoma reoccurrence. A small molecule compoundWP1130
has been shown to inhibit UCHL5 and is expected to functionally block proteasome [176].
Another small molecule compound b-AP15, which was initially identified in cell-based screen,
was found to increase the accumulation of polyubiquitin in the cells. Later b-AP15 was identi-
fied as an inhibitor of USP14 and UCHL5 [177]. Utilized in solid tumor and MM, b-AP15
showed considerable anti-cancerous effect in animal models. Thus, inhibiting these DUBs by
b-AP15, IU1 or related inhibitor may be of therapeutic benefits.
7. DUBs inhibitors
By regulating ubiquitin homeostasis, DUBs have been implicated in tumorigenesis as both its
overexpression or loss may drive oncogenesis. Hence, it is not surprising that deregulation of
DUBs can lead to severe pathological conditions. To target DUBs, a number of inhibitors either
specific for a single DUB or pan-enzyme inhibitors have been identified and are currently
explored for its risk-free use in patients. Another approach to target DUBs would be to identify
an antagonist that can bind to the DUB’s substrate for cancer therapy. DUBs show a great
degree of substrate specificity and have a well-defined active site such as the catalytic cysteine
which makes DUBs attractive targets for small molecule drug discovery. The active site cata-
lytic cysteine of DUBs is very reactive toward electrophiles. A majority of the DUBs inhibitors
are compounds with Michael acceptors such as α, β-unsaturated ketones which are capable of
forming covalent adducts with free thiols of nucleophilic cysteine which in turn blocks the
DUBs activity [178]. A diverse number of compounds ranging from synthetic small molecules
to natural compounds with inhibitory properties for DUBs have been identified and studied.
Several strategies can be used to target DUBs and we have summarized them in Figure 4 and
Table 2.
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7.1. Cyclopentenone prostaglandins
The induction of polyubiquitinated proteins in cells by prostaglandins of the PGJ2 class was
first reported by Fitzpatrick and coworkers [179]. DUB activity was shown to be inhibited by
prostaglandin PGJ2 which contains α, β-unsaturated ketones. PGJ2 is then further metabolized
to Δ12-PGJ2 and 15Δ-PGJ2 [179, 180] which show inhibitory effect toward UCHL3 and
UCHL1, respectively [167].
7.2. Chalcone compound with DUB inhibitory effect
A chalcone is an aromatic ketone and an enone that is centrally essential for a broad range of
biological compounds. These compounds have cross-conjugated α, β-unsaturated ketones and
accessible β-carbons that are important for inhibiting DUBs [181]. These compounds act as
either relatively specific or broad-spectrum inhibitors. For example, b-AP15 and its analogue
VLX1570 are relatively specific to USP14 and UCH37, whereas another chalcone compound
G5 possesses broad inhibitory effect [182, 183].
7.3. Other DUB inhibitors containing Michael acceptors
A small molecule, WP1130, which was derived from a compound with inhibitory activity for
Janus-activated kinase 2 (JAK2) kinase was reported to selectively inhibit the activity of USP5
along with USP9X, USP14, and UCH37 [176].
Figure 4. Pictorial representation of different strategies to target DUBs.
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S.
no.
Inhibitor Target (DUB) Major attributes Developmental
stage
1. LDN-57444 [195] UCHL-1 A potent active site directed inhibitor for UCHL-1
[195]; cell permeable inhibitor; decreases proteasome
activity
Preclinical
2. LDN-91946 [196] UCHL-1 Is able to inhibit UCHL-1 in a noncompetitive manner
[196]
Preclinical
3. 15Δ-PGJ2 UCHL-1 Is a metabolite of prostaglandin, PGJ2 that was
identified to retain inhibitory effects towards UCHL-1
by affecting overall structure and thus activity [305,
306]
4. AM146, RA-9, and
RA-14 [307]
UCHL-1 Are chalcones which act as partially selective DUBs
inhibitor and can inhibit UCHL-1 activity [307]
5. LS1 [308] UCHL-3 Inhibits UCHL-3, identified in FRET-based screen [309]
6. NSC112200 and
NSC267309 [310]
TRABID Inhibited the growth of colorectal tumor cell lines HCT-
116 and SW480 [310]
7. b-AP15 [177] UCHL-5 and
USP14
Anti-cancerous effect against solid tumor and multiple
myeloma in vivo
8. WP-1130 [176] USP9X, USP5,
USP14, UCH37,
UCHL-5
A small molecule, WP1130 serves as a pan DUBs
inhibitor which was derived from AG490 (JAK2
inhibitor) and reported to inhibit activity of several
DUBs [176]; elicits apoptosis of tumor cells
Preclinical
9. Pimozide [311] and
ML323 [312]
USP1 Works by blocking complex formation between USP1-
UAF1, which in turn inhibits USP1activity. ML323 and
related N-benzyl1-2-phenylpyrimidine-4-amine
derivatives shows higher selectivity and inhibitory
potency towards USP1/UAF1 than Pimozide [312]
Preclinical
10. ML364 [313] USP2 Is a small molecule inhibitor, which has been identified
to enhance Cyclin D1 degradation in colorectal cancer
and lymphoma model [313]
11. Vialinin A [185] USP4 and USP5 A natural compound isolated from Chinese mushroom
Thelephoravialis and has been shown to inhibit
enzymatic activity of USP4 and USP5 [185, 186]
Preclinical
12. P5091 [191] USP7 Selective inhibitor of USP7, triggers apoptosis in
multiple myeloma cells [191]
Preclinical
13. P22077 [192] USP7 and USP47 A specific inhibitor of USP7 identified by Progenra
[190]
Preclinical
14. Cpd14 [192] USP7 and USP47 Resulted in increase in p53 and induction of p21
protein in HCT-116 cells upon treatment [192]
15. HBX41, 108 [193] USP7 HBX 41,108 is an noncompititive reversible inhibitor
and it allosterically modulates the catalytic reaction of
USP7 [193]
Preclinical
16. HBX19, 818 [194] USP7 Binds selectively to the active site of USP7 [194] Preclinical
17. HBX28, 258 [194] USP7 Selective inhibitor for USP7
18. HBX90397 [314] USP8 Specifically target USP8 [116, 314]; inhibited cancer cell
growth
19. Spautin1 [315] USP10 and USP13 Induce Vps34 PI3K complex degradation [315] Preclinical
Targeting the Ubiquitin Proteasome System in Cancer
http://dx.doi.org/10.5772/intechopen.76705
221
7.4. Natural products with DUB inhibitory effect
A number of natural compounds have been identified to have DUB inhibitory effect. One of such
is Curcumin, which is a yellow pigment isolated from the Curcuma longa. Curcumin possesses
two α, β-unsaturated ketones moieties and has been linked with suppression of tumorigenesis
and various other diseases. It was reported that Curcumin accelerates polyubiquitinated pro-
tein accumulation at concentrations of 40 μM [184]. USP4 has been reported to be targeted by a
small natural compound known as Vialinin A. Vialinin A is isolated from the Chinese mush-
room Thelephoravialis and has been shown to inhibit the enzymatic activity of USP4 and USP5
[185, 186].
7.5. Synthetic small molecule DUB inhibitors
Several inhibitors have been developed to target the multifunctional deubiquitinating enzyme
USP7. USP7, also known as HAUSP, is probably the most attractive DUB in the field of cancer
biology. USP7 has been reported to regulate the function and stability of at least three impor-
tant tumor suppressor p53 [187], PTEN [188] and TIP60 [189]. Progenra identified P022077 as a
specific inhibitor for USP7 [190]. Other inhibitors of USP7 are P5091 and Cpd14, which triggers
apoptosis in MM cells and inhibits tumor growth [191, 192]. Other Hybrigenics compounds
which could inhibit USP7 function are HBX41108 [193], HBX19818 [194], and HBX28258 [194].
An isatin O-acyl oxime, LDN-57444 is a most potent active site directed inhibitor for UCHL-1
[195]. LDN-91946 is another compound which was identified as a hit in an in vitro screen for
identifying blockers of Ub-AMC activity and was able to inhibit UCHL-1 in a noncompetitive
manner [196].
Despite the multitude of inhibitors identified to target DUBs, so far, no DUB inhibitors are
approved for clinical use. Only a few of these inhibitors, such as VLX1570, are in clinical trial for
S.
no.
Inhibitor Target (DUB) Major attributes Developmental
stage
20. Mitoxantrone [316] USP11 Preclinical
21. IU1 [167] USP14 Cell permeable; reversible; encourages ubiquitin
dependent protein degradation in vitro
Preclinical
22. GSK2643943A [317] USP20 Identified by GSK from a screen involving
compounds targeting USP20/Ub-Rho. It has an
IC50 of 160 nM [317]
Preclinical
23. 15-
oxospiramilacetone
[318]
USP30 15-oxospiramilacetone is the only inhibitor for USP30
defined so far which can be used in case of some
mitochondrial dysfunctions [318]; natural compound
from spiramine A; induce mitochondrial fusion
Preclinical
24. PR619 [319] Broad range
DUBs inhibitor
Nonselective, noncompetitive, reversible; results in
accumulation of ubiquitinated proteins
25. 1,10-
phenanthroline
[320, 321]
JAMM type
isopeptidase
Chelates active site Zn2+
Table 2. Different inhibitors and their target DUBs.
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cancer therapy. Out of 98 DUBs, only several DUBs have been explored structurally providing a
platform for understanding, identifying, and validating various DUB inhibitors for clinical usage.
8. Conclusion
The UPS is implicated in several human diseases such as neurodegenerative disease, inflam-
mation, bacterial and viral infection and most importantly, in cancer. The type of ubiquitin
linkages formed/cleaved with the help of a cascade of enzymes (E1, E2, E3/DUBs) intensifies
biological complexities. Hence, it is important to discover and identify the targets for thera-
peutic intervention. One of the strategies that can be used is targeting components of the UPS.
Over the past 35 years, our knowledge and understanding of the UPS has significantly
increased and it is evident that the UPS plays critical roles in various important cellular
functions and can regulate both structural and functional behavior of cells. The success of
Bortezomib provides a proof-of-concept to expand the use of other inhibitors targeting differ-
ent components of UPS system in cancer. However, the results were not satisfying due to
challenges in bringing these inhibitors to clinic. This is mostly because E3 ligases and DUBs
have multiple substrates which makes it complicated. Therefore, it is critical to find the right
target(s) for a specific cancer, to understand how the target functions and eventually find the
finest way to effectively manipulate these targets for treatment intervention.
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